LAURA WELBORN: Open Payments
NPI 1265403661 · TOPEKA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,419 in 72 payments from 13 companies in 2025. Trend: 2023 $1,547 · 2024 $1,290 · 2025 $2,419
Food & beverage: $1,528Travel & lodging: $891
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 12 | $1,342 |
| ABBVIE INC. | 22 | $303 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $161 |
| Janssen Biotech, Inc. | 7 | $156 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $148 |
| Ipsen Biopharmaceuticals, Inc | 4 | $71 |
| Regeneron Healthcare Solutions, Inc. | 3 | $63 |
| Ardelyx, Inc. | 3 | $57 |
| Intercept Pharmaceuticals, Inc. | 2 | $31 |
| QOL Medical, LLC | 1 | $27 |
Products named: TREMFYA, XIFAXAN, SKYRIZI, ENTYVIO, REZDIFFRA, IQIRVO, DUPIXENT, RINVOQ.
Industry payments across KS — which companies pay providers there.
